Lack of Efficacy of Concomitant 5-Aminosalicylic Acid With Vedolizumab in Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis
Lay Summary We evaluated whether adding 5-aminosalicylic acid (5-ASA) to vedolizumab therapy helps prevent relapse in ulcerative colitis (UC) and Crohn’s disease (CD). Using a large Japanese claims database, we found no benefit of 5-ASA in maintaining remission for either UC or CD. These findings suggest that combining 5-ASA with vedolizumab may not be beneficial.
Authors
- Masaki Ominami (ORCID: https://orcid.org/0000-0002-9692-0420)
- Yuji Nadatani (ORCID: https://orcid.org/0000-0001-7081-8746)
- Shusei Fukunaga (ORCID: https://orcid.org/0000-0002-9336-8271)
- Rieko Nakata (ORCID: https://orcid.org/0000-0001-9977-7239)
- Koji Fujimoto (ORCID: https://orcid.org/0009-0004-7768-2553)
- Hirotsugu Maruyama (ORCID: https://orcid.org/0000-0002-8728-8101)
- Koji Otani (ORCID: https://orcid.org/0000-0001-9075-6415)
- Shuhei Hosomi (ORCID: https://orcid.org/0000-0002-8808-5672)
- Yumie Kobayashi (ORCID: https://orcid.org/0000-0002-5747-6697)
- Fumio Tanaka (ORCID: https://orcid.org/0000-0002-9186-1249)
- Yasuhiro Fujiwara (ORCID: https://orcid.org/0000-0002-1225-1785)
- Yu Nishida (ORCID: https://orcid.org/0000-0003-3369-5059)
Institutions
- Osaka City University (JP)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-05-21
- DOI
- https://doi.org/10.1093/ibd/izaf088
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82